Global Markets for Media, Sera and Reagents in Biotechnology -- Focus on the U.S.

Report Highlights

• The global market for media, sera and reagents used in biotechnology was valued at $2.3 billion in 2009, $2.5 billion in 2010 and is estimated to have reached nearly $2.8 billion at the end of 2011. The market is expected to reach $4.2 billion by 2016, a compound annual growth rate (CAGR) of 8.8%.
• The U.S. market segment for cell culture products was $1.3 billion in 2009 and $1.4 billion in 2010. This market is expected to increase from $1.5 billion in 2011 to nearly $2.3 billion by 2016, at a CAGR of 8.3%.
• The U.S. market segment for cell culture media was $399.2 million in 2009 and $427.7 million in 2010. This market is estimated to increase from $460.3 million in 2011 to $655.5 million by 2016, a CAGR of 7.3%.

INTRODUCTION

STUDY OBJECTIVES

BCC’s goal in conducting this study is to provide an overview of the current and future characteristics of the global market for media, sera and the reagents used in biotechnology.  The key objective is to present a comprehensive analysis of the current market and its future direction in the media, sera and biotechnology reagents markets as an important tool for the cell culture industry.

This report explores present and future strategies within the media and sera market, including reagents used in biotechnology.  The improvisation of the market, the setbacks and the needs of the market are discussed in this report.  The types of cell cultures and the products from cell culture technology are also presented in this report.  The advantages and disadvantages for the use of various types of media are also covered in this report.

A detailed analysis of the cell culture industry structure has been conducted.  This includes the biotechnology reagents, media and the sera used.  Revenues are broken down by global region.  Sales figures are estimated for the five-year period from 2011 through 2016.

Applications for the cell culture industry—media, sera and reagents used in biotechnology—are also discussed in the report, with an emphasis on the usage in the research, production and contract segments.  The report also covers significant patents in each segment.

REASONS FOR DOING THIS STUDY

Demand for cell culture products, namely media, sera and reagents, is increasing, with the increasing demand for biopharmaceuticals.  Cell culture, a crucial component of the life sciences industry, has witnessed major development during the past three decades.  R&D spending, along with increasing competition, patent expiries, new technologies and an international marketplace are moving the cell culture process in a new direction.  As cell culture technologies evolved, a number of disciplines such as cell biology, genetic engineering, protein chemistry, genomics and chemical engineering have been successfully incorporated into the cell culture field.

Acquisition strategies and collaborations by companies are also covered in this report.  This study also discusses the strength and weaknesses of the different types of media used in light of the new technologies, growing competition and changing customer needs.

INTENDED AUDIENCE

This study contributes to the areas of market growth in the cell culture industry from the point of view of manufacturers and users.  Biotechnological companies, physicians, the pharmaceutical and biopharmaceutical industries, hospitals and research institutes will find this study to be of interest.

SCOPE OF THE STUDY

The scope of this study encompasses the biotechnology, pharmaceutical and medical markets.  BCC analyzes each market and its applications by its need for development of new medications through cell culture techniques, the regulatory environment, technology involved, market projections and market share.  Technological issues include the latest trends and developments.

METHODOLOGY

BCC conducted a comprehensive literature search, which included technical newsletters and journals, and many other sources.  Data was collected through interviews and correspondence with various analytical, chemical, pharmaceutical and biotechnical experts.  Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.

INFORMATION SOURCES

Many companies within the industry were surveyed to obtain data for this study.  Included were manufacturers and end users of biopharmaceuticals, and pharmaceutical companies through their production, research and contract manufacturing/research lines.  Data were gathered from various industry sources.  BCC spoke with officials and physicians within the industry, consulted newsletters, company literature, product literature and a host of technical articles, journals, indexes and abstracts.  Exhaustive investigations of databases by key terminology were completed.  In addition, data were compiled from current financial, trade and government sources.

BCC ONLINE SERVICES

By directing your browser to BCC’s website at www.bccresearch.com, you will be able to do the following:

• Examine its complete catalog of technology market research reports, tables of content and order directly from BCC Research.
• Subscribe to any of its more than 20 monthly technology/marketing newsletters.
• Read announcements of upcoming reports and newly launched newsletters.
• Register for BCC’s well-known conferences.
• Request additional information about any BCC product.
• Take advantage of special offers.

To reach this important new information resource, go to www.bccresearch.com

DISCLAIMER

The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature.  This information does not constitute managerial, legal or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature.  The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.

Analyst Credentials

Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.